X
<

Why Gilead’s Valuation Is Low Compared to Peers

PART:
1 2 3 4 5
Part 4
Why Gilead’s Valuation Is Low Compared to Peers PART 4 OF 5

How Gilead’s Liver Disease Drugs Portfolio Performed

Gilead’s liver disease drugs   

As discussed earlier, Gilead’s (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver disease, oncology, cardiovascular, inflammation, respiratory, and others. Over 50% of revenues comes from antiviral products from the liver disease franchise.

How Gilead’s Liver Disease Drugs Portfolio Performed

How Gilead’s Liver Disease Drugs Portfolio Performed

Receive e-mail alerts for new research on GILD:

Interested in GILD?
Don’t miss the next report.


Success!
You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success!
has been added to your Ticker Alerts.

Success!
has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Liver disease drugs portfolio  

The liver disease drugs portfolio includes drugs like Sovaldi, Viread, Harvoni, Hepsera, and Epclusa.

Harvoni

Harvoni is Gilead’s best-selling drug. Harvoni is used with or without ribavirin for the treatment of chronic hepatitis C virus of genotype-1, genotype-4, genotype-5, and genotype-6. Harvoni reported a decline in revenues of $9.1 billion for 2016 as compared to $13.9 billion for 2015.

Sovaldi

Sovaldi is a drug used in combination with other antivirals for the treatment of chronic hepatitis C virus of genotype-1 to genotype-4. Sovaldi reported revenues of $4.0 billion in 2016 as compared to $5.3 billion for 2015.

Viread

Viread is used in combination with other antiretrovirals for the treatment of patients with HIV-1 infection. It’s also used for the treatment of patients with Hepatitis B virus infection. However, the drug Viread should not be used in combination with other drugs like Atripla, Complera, Stribild, and Truvada. Viread reported revenues of $1.2 billion for 2016 as compared to $1.8 billion for 2015.

Epclusa  

Epclusa is a new drug for the treatment of chronic Hepatitis C infection of Genotype-1 to Genotype-6 with or without cirrhosis. For patients who have advanced cirrhosis, the drug is used in combination with Ribavirin. Epclusa will be a new blockbuster drug for the treatment of patients with Hepatitis C infections. The drug reported revenues of $1.8 billion for 2016.

Some of the approved treatments for HCV include Zepatier from Merck (MRK), Daklinza from Bristol-Myers Squibb (BMY), Technivie and Viekira Pak from AbbVie (ABBV), and Olysio for Johnson & Johnson (JNJ).

To divest the risk, investors can consider ETFs like the SPDR S&P Biotech ETF (XBI), which holds ~2.2% of its total assets in Gilead Sciences.

X

Please select a profession that best describes you: